Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.
Morganti AG, Cellini F, Mignogna S, Padula GD, Caravatta L, Deodato F, Picardi V, Macchia G, Cilla S, Buwenge M, Di Lullo L, Gambacorta MA, Balducci M, Mattiucci GC, Autorino R, Valentini V. Morganti AG, et al. Among authors: di lullo l. Future Oncol. 2016 Mar;12(6):779-87. doi: 10.2217/fon.15.350. Epub 2016 Feb 1. Future Oncol. 2016. PMID: 26829128 Clinical Trial.
External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study.
Mattiucci GC, Morganti AG, Valentini V, Ippolito E, Alfieri S, Antinori A, Crucitti A, D'Agostino GR, Di Lullo L, Luzi S, Mantini G, Smaniotto D, Doglietto GB, Cellini N. Mattiucci GC, et al. Among authors: di lullo l. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):831-8. doi: 10.1016/j.ijrobp.2009.02.013. Epub 2009 May 8. Int J Radiat Oncol Biol Phys. 2010. PMID: 19427747 Clinical Trial.
Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and neck cancer.
Morganti AG, Mignogna S, Deodato F, Massaccesi M, Cilla S, Calista F, Serafini G, Digesú C, Macchia G, Picardi V, Caravatta L, Di Lullo L, Giglio G, Sallustio G, Piermattei A, Cellini N, Valentini V. Morganti AG, et al. Among authors: di lullo l. Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1073-80. doi: 10.1016/j.ijrobp.2009.12.020. Epub 2010 May 14. Int J Radiat Oncol Biol Phys. 2011. PMID: 20472342
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
Adamo V, Lorusso V, Rossello R, Adamo B, Ferraro G, Lorusso D, Condemi G, Priolo D, Di Lullo L, Paglia A, Pisconti S, Scambia G, Ferrandina G. Adamo V, et al. Among authors: di lullo l. Br J Cancer. 2008 Jun 17;98(12):1916-21. doi: 10.1038/sj.bjc.6604409. Epub 2008 May 20. Br J Cancer. 2008. PMID: 18493232 Free PMC article. Clinical Trial.
Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, Trivisonne R, Buzzi F, De Signoribus G, Tuveri G, Rossi G, Di Lullo L, Sturba F, Morale D, Catanzani S, Pilone A, Bonsignori M, Battelli T. Mazzanti P, et al. Among authors: di lullo l. Lung Cancer. 2003 Jul;41(1):81-9. doi: 10.1016/s0169-5002(03)00140-5. Lung Cancer. 2003. PMID: 12826316 Clinical Trial.
157 results